Legal entity
regulation is the sole category represented across all 3 tracked stories. Of the tracked stories, 3 of 3 also mention Duane Boise, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.1 for the broader beat in this window.
Last mentioned: Aug 10, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 3 tracked stories. Of the tracked stories, 3 of 3 also mention Duane Boise, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.1 for the broader beat in this window. The 29-day window averages about 0.7 stories each week. Their average consequence score of 6 runs below the beat's 6.1 for that window. We currently track 3 Legal stories that mention MMJ International Holdings, published between July 13, 2026 and August 10, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 362 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MMJ International Holdings. Shared-story counts are live from our verified record — not editorial picks.
Post-Hearing Briefs Due
Parties submit final briefs to Administrative Law Judge Derek C. Julius, summarizing their arguments on the evidentiary record and legal standards. The recommendation on rescheduling is expected to follow shortly thereafter.
Rescheduling Hearing Testimony
Under subpoena, Dr. Akinfiresoye testifies in the marijuana rescheduling proceeding that marijuana fails the first three factors of the DEA's five-factor test, directly contradicting the HHS Schedule III recommendation.
ALJ Hearing on Marijuana Rescheduling
A seven-day administrative hearing is held in Arlington, Virginia, debating whether marijuana has a 'currently accepted medical use' without MMJ's testimony or evidence.
DEA Excludes MMJ from Rescheduling Hearing
The DEA denies MMJ International Holdings' request to participate in the upcoming administrative hearing, asserting that its evidence raises only questions of law.
DEA Scientific Data Review Published
Dr. Luli Akinfiresoye authors the DEA's internal Scientific Data Review on marijuana, reportedly concluding that marijuana lacks sufficient, reproducible scientific evidence for accepted medical use.
ALJ Julius's upcoming recommendation in the DEA marijuana rescheduling hearing may challenge the government's novel approach of limiting Schedule III status to state-licensed medical programs, after DEA scientist testimony cast doubt on whether such programs satisfy the Controlled Substances Act's rigorous medical-use standard.
Source: nashvilleherald.com · pittsburghstar.com
DEA pharmacologist Dr. Luli Akinfiresoye testified that marijuana fails the agency's historical scientific standard for accepted medical use, directly contradicting the HHS recommendation to reschedule. This intra-agency conflict exposes the proposed Schedule III rule to a likely arbitrary-and-capricious challenge, redefining the evidentiary landscape for controlled substance rulemaking.
Source: newjerseytelegraph.com · pr-inside.com
MMJ International Holdings alleges the DEA violated administrative law by excluding it from marijuana rescheduling hearings, despite spending $10 million on FDA-pathway development. The exclusion raises due process and APA concerns that could imperil the final rule.
Source: saltlakecitysun.com · memphissun.com
MMJ International Holdings is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
